Piperacillin, a new penicillin active against many bacteria resistant to other penicillins
about
beta-Lactamases in laboratory and clinical resistanceComparative study of piperacillin, ticarcillin, and carbenicillin pharmacokinetics.Comparative bactericidal effects of azlocillin and ticarcillin against Pseudomonas aeruginosaComparative in vitro appraisal of piperacillin, including its activity against Salmonella typhi.Activities of cefoxitin and cefotetan against Mycobacterium fortuitum infections in miceImipenem antagonism of the in vitro activity of piperacillin against Pseudomonas aeruginosa.Natural occurrence and industrial applications of D-amino acids: an overview.Susceptibility of the anaerobic bacteria, group D streptococci, Enterobacteriaceae, and Pseudomonas to semisynthetic penicillins: carbenicillin, piperacillin, and ticarcillinIn vitro activity of piperacillin, ticarcillin, and mezlocillin alone and in combination with aminoglycosides against Pseudomonas aeruginosa.In vitro activities of enoxacin, ticarcillin plus clavulanic acid, aztreonam, piperacillin, and imipenem and comparison with commonly used antimicrobial agents.Pharmacokinetics of piperacillin in patients with moderate renal failure and in patients undergoing hemodialysis.Competition of beta-lactam antibiotics for the penicillin-binding proteins of Neisseria gonorrhoeaeClinical evaluation of the therapeutic efficacy and tolerability of piperacillin.Comparative in vitro activities of azlocillin-cefotaxime and azlocillin-tobramycin combinations against blood and multi-drug resistant bacterial isolatesPiperacillin pharmacokinetics in pediatric patientsNew Frontiers in DruggabilityStatistical comparison of the antibacterial activities of broad-spectrum penicillins against gram-negative bacilliProspective randomized trial of piperacillin monotherapy versus carboxypenicillin-aminoglycoside combination regimens in the empirical treatment of serious bacterial infectionsIn vitro susceptibilities of 393 recent clinical isolates to WIN 49375, cefotaxime, tobramycin, and piperacillin.Use of ureidopenicillins for selection of plasmid vector transformants in Pseudomonas aeruginosa and Pseudomonas putida.Susceptibility of enterococci and epidemiology of enterococcal infection in the 1980sAnalysis of the interactions between piperacillin, ticarcillin, or carbenicillin and aminoglycoside antibiotics.Phosphonopeptides as antibacterial agents: alaphosphin and related phosphonopeptides.Piperacillin susceptibility tests by the single-disk agar diffusion techniqueAgar disk diffusion susceptibility characteristics of azlocillin, carbenicillin, mezlocillin, piperacillin, and ticarcillinPharmacokinetics of intravenous piperacillin in patients undergoing chronic hemodialysis.Pharmacokinetics of intravenous piperacillin administration in patients undergoing on-line hemodiafiltration.In vitro activity of piperacillin compared with that of carbenicillin, ticarcillin, ampicillin, cephalothin, and cefamandole against Pseudomonas aeruginosa and EnterobacteriaceaeComparative in vitro activity of azlocillin, ampicillin, mezlocillin, piperacillin, and ticarcillin, alone and in combination with an aminoglycoside.Enhanced liposome-mediated activity of piperacillin against staphylococci.In vitro activity of CGP 31523A, a broad-spectrum cephalosporin, in comparison with those of other agents.In vitro comparison of N-formimidoyl thienamycin, piperacillin, cefotaxime, and cefoperazone.Clinical evaluation of piperacillin with observations on penetrability into cerebrospinal fluid.Activities of new beta-lactam antibiotics against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.In vitro activity of apalcillin compared with that of other new penicillins and anti-Pseudomonas cephalosporins.Comparative in vitro activities of beta-lactam-tobramycin combinations against Pseudomonas aeruginosa and multidrug-resistant gram-negative enteric bacilliSingle-dose pharmacokinetics of piperacillin and tazobactam in infants and children.Piperacillin sodium: antibacterial spectrum, pharmacokinetics, clinical efficacy, and adverse reactions.Synergistic activity of piperacillin in combination with beta-lactamase inhibitors.Comparative evaluation of piperacillin in vitro
P2860
Q24669605-0290E164-74E3-4205-95FB-0F8A024EF613Q33726819-A3F5CD24-CA8B-42B6-9178-AA501C62F346Q33731600-D87B0EF7-7044-49A6-B434-D46B5053B3F5Q33734105-05CDBE4B-9C82-4A03-8A55-255A9087E3D5Q33737910-58BBE2D7-1099-4321-9497-B4941E19751CQ33737945-579FCCBC-8164-4246-B4F1-D4715DC7F541Q34022822-9BAA02A6-D708-4D66-ABB2-EC157A266BDEQ34503672-B6DFF2E3-EB04-47A9-8916-89D65B7FE415Q35574121-3A21BDBF-EAC6-4308-9EF5-C5EED1841B3CQ35646255-F1949CC2-5164-4464-8E28-B4289497CFCBQ35668811-7ADF3E90-C438-4E4A-9F5F-A0B7ED840906Q35670976-92BF75D4-5AAA-47E6-86F8-3CE1C17C56FAQ35712384-F814F973-5DA5-422C-92EC-AA29D2AD0BB6Q35713674-019EF89E-E6A3-4785-A1FF-B2EDB97CD02EQ35716595-7B84B641-02EA-4FF3-975C-2142BD0D13FFQ35730955-97C6CB93-15CE-4109-921E-096F8C2F5F22Q35749296-A7D06459-E4D4-45F8-9BC5-821A639AEAF0Q35754154-F38A739C-5075-4C06-9CBE-7C5D7E06215EQ35758070-8DB5652E-020F-41F1-BC12-A335728D7650Q36298274-16691710-01DD-4FA7-AFE1-D3352F032B81Q36473436-D6746EA0-6363-45E8-8FAE-8D8EE5601E7DQ36474362-F87D8FA7-2F21-4DD7-B5B5-CD3F164ACAD3Q36480656-6372EEC7-ED95-49F5-A842-F8CB2F23926DQ36484041-0B921163-DFF5-4F5F-991E-EA5DEC5B8B6BQ36485549-987F5925-0FE7-43D2-9AE4-26C8328C2F72Q36486623-169463EC-2E11-43F3-8AEC-E3942046BC47Q37274643-A70C0976-A66C-4109-A5AF-ADA32F735DABQ39675313-DFB498D9-B581-45A3-8A1C-D4CA1CEAC4AEQ39675343-ED081942-E05F-4EEC-8229-36352D52200FQ39833713-17BC01BB-BB4D-42C9-85F2-3F9FD95BFD61Q39849432-36E73475-61AF-4B21-B6EB-F4C4DDF410E8Q39855480-0A6E4D1A-0E58-4D0A-B7E9-BF3F68484163Q39855864-5B0FF27F-44F8-4290-88FB-A78833883EAFQ39855932-DF6B76A2-5518-4083-8629-006D4DEFE209Q39857223-5113FA1D-A261-4B16-8D88-F48853FBDD71Q39857307-6C322978-0E43-4BD3-AB22-9A9EF225BCC5Q39867395-5803B82D-5AF1-44DD-BA8C-F7FDFD81C09EQ40114428-0E93B07A-D11C-400D-B3CA-7329520C8EB1Q40282958-E69C7B48-6C95-4C92-BB8E-71B5CDC8322FQ40411977-6444D414-3B5C-41E9-A126-5A92CA0AEC5B
P2860
Piperacillin, a new penicillin active against many bacteria resistant to other penicillins
description
1978 nî lūn-bûn
@nan
1978 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1978 թվականի մարտին հրատարակված գիտական հոդված
@hy
1978年の論文
@ja
1978年論文
@yue
1978年論文
@zh-hant
1978年論文
@zh-hk
1978年論文
@zh-mo
1978年論文
@zh-tw
1978年论文
@wuu
name
Piperacillin, a new penicillin ...... resistant to other penicillins
@ast
Piperacillin, a new penicillin ...... resistant to other penicillins
@en
Piperacillin, a new penicillin ...... resistant to other penicillins
@nl
type
label
Piperacillin, a new penicillin ...... resistant to other penicillins
@ast
Piperacillin, a new penicillin ...... resistant to other penicillins
@en
Piperacillin, a new penicillin ...... resistant to other penicillins
@nl
prefLabel
Piperacillin, a new penicillin ...... resistant to other penicillins
@ast
Piperacillin, a new penicillin ...... resistant to other penicillins
@en
Piperacillin, a new penicillin ...... resistant to other penicillins
@nl
P2860
P356
P1476
Piperacillin, a new penicillin ...... resistant to other penicillins
@en
P2860
P304
P356
10.1128/AAC.13.3.358
P407
P577
1978-03-01T00:00:00Z